Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on ...
Company presentation scheduled on Tuesday, March 4th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses ...
D2 Capital Advisors arranged $26,000,000 in permanent financing for a recently completed lab and R&D building in Wilmington's Chestnut Run Innovation & Science Park (CRISP). The 80,0000 square foot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback